AEG 3482
Modify Date: 2024-01-04 18:42:59
AEG 3482 structure
|
Common Name | AEG 3482 | ||
|---|---|---|---|---|
| CAS Number | 63735-71-7 | Molecular Weight | 280.326 | |
| Density | 1.8±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C10H8N4O2S2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of AEG 3482AEG3482 is a potent antiapoptotic compound that inhibits Jun kinase (JNK) activity through induced expression of heat shock protein 70 (HSP70). AEG3482 directly binds HSP90, thereby facilitating HSF1-dependent expression of HSP70 and HSP25[1]. |
| Name | 6-phenylimidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide |
|---|---|
| Synonym | More Synonyms |
| Description | AEG3482 is a potent antiapoptotic compound that inhibits Jun kinase (JNK) activity through induced expression of heat shock protein 70 (HSP70). AEG3482 directly binds HSP90, thereby facilitating HSF1-dependent expression of HSP70 and HSP25[1]. |
|---|---|
| Related Catalog | |
| Target |
JNK[1] |
| In Vitro | AEG3482 (0.3-30 μM; 2 d) inhibits nerve growth factor (NGF) withdrawal-induced death in SCG neurons, with an EC50 of ∼20 μM[1]. AEG3482 (1-80 μM; 40 h) inhibits p75NTR- and NRAGE- mediated apoptosis of PC12 cells in a dose-dependent manner[1]. AEG3482 (10-40 μM; 30 h) inhibits p75NTR- and NRAGE-mediated JNK activation in PC12 cells[1]. Apoptosis Analysis[1] Cell Line: PC12 cells Concentration: 1, 2.5, 5, 10, 20, 40, 80 μM Incubation Time: 40 hours Result: Reduced p75NTR- or NRAGE-induced cell death by greater than 90% at the concentration of 40 μM. Exerted a slight toxic effect in cells infected with the LacZ control at the concentration of 80 μM. Western Blot Analysis[1] Cell Line: PC12 cells Concentration: 10, 20, 40 μM Incubation Time: 30 hours Result: Attenuated p75NTR- and NRAGE-induced c-Jun phosphorylation and caspase-3 cleavage, and the levels of c-Jun protein. |
| References |
| Density | 1.8±0.1 g/cm3 |
|---|---|
| Molecular Formula | C10H8N4O2S2 |
| Molecular Weight | 280.326 |
| Exact Mass | 280.008881 |
| PSA | 126.97000 |
| LogP | 1.32 |
| Index of Refraction | 1.835 |
| Precursor 2 | |
|---|---|
| DownStream 0 | |
|
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.
Nat. Commun. 6 , 8746, (2015) Metastatic tumour recurrence due to failed treatments remains a major challenge of breast cancer clinical management. Here we report that interleukin-1 receptor-associated kinase 1 (IRAK1) is overexpr... |
|
|
The Ser/Thr kinase MAP4K4 drives c-Met-induced motility and invasiveness in a cell-based model of SHH medulloblastoma.
Springerplus 4 , 19, (2015) Medulloblastoma (MB) comprises four molecularly and genetically distinct subgroups of embryonal brain tumors that develop in the cerebellum. MB mostly affects infants and children and is difficult to ... |
| hms1538b12 |
| 6-Phenylimidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide |
| Imidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamide, 6-phenyl- |
| unii-7ezf1a283n |